PDS Biotechnology Corporation stock is up 14.51% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November. In the last 3 Unusual Options Trades, there were 3 CALLs. 100% of analysts rate it a buy.
PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.